An autonomous surgical robot performs a complete invasive human operation without human intervention before 2032.
Current surgical robots assist human doctors rather than operating autonomously. Resolves if regulators approve and a robotic system executes a full surgical procedure independently.
Across 6 frontier models answering independently, the panel has all but ruled it out: the median is 11%.
They do not agree: GPT puts it at 71% and Qwen at 3%, 68 points apart. A spread that wide usually means the question turns on something none of them can see yet.
Nothing is settled until 26 Oct 2036, when the outcome is checked against sources and every number above gets a permanent score.
What each one said
-
GPTOpenAI
It hinges on narrow-indication autonomy winning regulatory clearance before broader “robot surgeon” claims matter.
- Companies such as MIRA Surgical and Johnson & Johnson must complete pivotal trials and secure FDA authorization, likely first for routine soft-tissue tasks.
- The base rate is favorable over a decade: autonomous bone cutting and supervised autonomous suturing already have clinical precedents, but full procedures remain harder.
- A published FDA-cleared, no-intervention case in a constrained procedure would sharply raise confidence; serious adverse events or trial failures would cut it.
71% -
ClaudeAnthropic
Hinges on regulatory approval of fully autonomous invasive surgery, not just research demos, before late 2032.
- Current systems like STAR have only done autonomous soft-tissue suturing in constrained lab/animal settings, far from full invasive human ops.
- Regulatory bodies (FDA, EMA) move cautiously on autonomy in high-risk medical devices, with no clear pathway yet established for full autonomy approval.
- A breakthrough demonstration plus fast-tracked regulatory pilot program for a narrow procedure type could shift this, but no such program is imminent as of 2026.
12% -
DeepSeekDeepSeek
Whether any regulator lets a robot cut a whole operation solo, and no one is close to filing that.
- FDA has cleared only assistive platforms like da Vinci and Mako; no autonomous full-procedure system has even entered an IDE trial as of 2026.
- The gap is not dexterity but closed-loop autonomy under adverse events, which needs years of cadaver and animal data before a first-in-human filing.
- Precedent: autonomous driving took a decade from demo to limited permits, and surgery carries higher liability, so 2032 is roughly one regulatory cycle too early.
12% -
GrokxAI
FDA-class approval plus one unsupervised full invasive case in a living patient by 31 Dec 2031.
- No regulator has ever cleared unsupervised invasive surgery; even limited-autonomy trials require multi-year animal-then-human data that has not started.
- Lab demos (STAR anastomosis) have not left the animal lab; da Vinci and peers remain fully teleoperated with no 5-year path to unsupervised OR use.
- A 2027 porcine full-procedure plus IDE filing would move the needle, but none is publicly scheduled.
9% -
GeminiGoogle
Regulatory liability and unpredictable human anatomy make full autonomy without intervention unviable before 2032.
- FDA De Novo or PMA pathways require extensive safety data that zero fully autonomous human clinical trials currently support.
- While STAR sutured pig intestines in 2022, transitioning to a full invasive human procedure exceeds the remaining 5-year timeline.
- A successful trial of autonomous appendectomy or cholecystectomy in a major jurisdiction by 2028 would sharply raise these odds.
8% -
QwenAlibaba
FDA approval alone for a novel autonomous surgical device class would take 5+ years even if a system were submission-ready today.
- The most advanced system (STAR, Johns Hopkins) has only done autonomous suturing on porcine tissue as of 2022; no human trials have begun.
- FDA 510(k) or PMA pathways for a first-of-kind autonomous surgical robot would require multi-year clinical trials with no existing predicate device.
- A surprise FDA breakthrough approval or a foreign regulator (e.g., China's NMPA) fast-tracking a system would be the only path to move this above 10%.
3%
6 of 6 models answered · 68 points between the highest and lowest. None was shown the market price.
Question sourced from a news sweep on 29 Oct 2026. Forecast by google/gemini-3.8-flash, anthropic/claude-sonnet-5, openai/gpt-5.6-terra, x-ai/grok-4.6, deepseek/deepseek-v4.1-flash, qwen/qwen3.8-max-0902 via OpenRouter.